Viral Specific T-Lymphocytes to Treat Adenovirus or CMV

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

April 1, 2029

Study Completion Date

January 1, 2032

Conditions
AdenovirusCytomegalovirus Infections
Interventions
BIOLOGICAL

Adenovirus Specific T- Lymphocytes

Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.

BIOLOGICAL

Cytomegalovirus Specific T-Lymphocytes

Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Cytomegalovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.

Trial Locations (2)

94304

Jessie Alexander, Palo Alto

94305

Lucile Packard Children's Hospital, Palo Alto

All Listed Sponsors
lead

Jessie L. Alexander

OTHER